OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
February 15, 2024 09:31 ET
|
OnKure, Inc.
BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H. as Chief Medical Officer. Dr. Agresta brings more than 15 years of...
OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219
January 04, 2024 09:00 ET
|
OnKure, Inc.
BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of OKI-219,...
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
September 20, 2023 09:41 ET
|
OnKure, Inc.
BOULDER, Colo., Sept. 20, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces $54 Million Series C Financing
May 23, 2023 07:00 ET
|
OnKure, Inc.
BOULDER, Colorado, May 23, 2023 (GLOBE NEWSWIRE) -- OnKure, Inc. a precision oncology company, today announced that it has successfully closed a $54 million Series C financing. The financing was led...
OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations
December 06, 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., Dec. 06, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
June 21, 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma
June 02, 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
April 25, 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., April 25, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
April 08, 2022 13:00 ET
|
OnKure, Inc.
OKI-179 demonstrated chemical synthetic lethality when combined with MEK and BRAF inhibitors in RAS pathway mutated cancer models The Company plans to initiate the OKI-179-230 Phase 1b/2 trial of...
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
March 08, 2022 16:30 ET
|
OnKure, Inc.
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...